ContraFect Corporation
CFRXQOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$107
P/E Ratio—
52W High$0.0005
52W Low$0.00001
ContraFect Corporation (CFRXQ) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CFRXQ · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 14, 2023EPS Actual
-$0.50
Est. -$0.66 · +24.1%
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 14, 2023
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
CFRXQ reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$22.40 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | May 29, 2026 | — | — | — | — | — | — |
| ◌ Q2 FY2026 | May 11, 2026 | -$22.40 | — | — | — | $0.00B | — |
| ◌ Q1 FY2026 | Feb 25, 2026 | -$23.60 | — | — | — | $0.00B | — |
| ◌ Q2 FY2025 | May 2, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Mar 27, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Dec 26, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Jul 23, 2024 | -$0.69 | — | — | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$22.40
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 29, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026
EPS Actual
—
EPS Est.
-$22.40
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 25, 2026
EPS Actual
—
EPS Est.
-$23.60
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 2, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 27, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Dec 26, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Jul 23, 2024
EPS Actual
—
EPS Est.
-$0.69
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $-0.69 | $-0.69 | $-0.69 | 1 |
| Q2 FY2029 | $-0.66 | $-0.66 | $-0.66 | 1 |
| Q1 FY2029 | $-1.81 | $-1.81 | $-1.81 | 1 |
| Q4 FY2028 | $-0.69 | $-0.69 | $-0.69 | 1 |
| Q3 FY2028 | $-0.66 | $-0.66 | $-0.66 | 1 |
| Q2 FY2028 | $-1.81 | $-1.81 | $-1.81 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2023 | Nov 14, 2023 | +24.1% | $0.05 | $0.06 | +15.38% |
| ▼ Q3 FY2023 | Aug 14, 2023 | -7.2% | $0.97 | $0.96 | -1.03% |
| ▲ Q1 FY2023 | Mar 31, 2023 | +93.6% | $2.19 | $1.83 | -16.44% |
Q4 FY2023+15.38%
Report Date
Nov 14, 2023
EPS Beat/Miss
+24.1%
Price Before
$0.05
Price After
$0.06
Q3 FY2023-1.03%
Report Date
Aug 14, 2023
EPS Beat/Miss
-7.2%
Price Before
$0.97
Price After
$0.96
Q1 FY2023-16.44%
Report Date
Mar 31, 2023
EPS Beat/Miss
+93.6%
Price Before
$2.19
Price After
$1.83
Avg Beat Reaction-0.53%
Avg Miss Reaction-1.03%
Beat Rate2 / 3 quarters
Largest Move-16.44% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CFRXQ ends December
ContraFect Corporation (CFRXQ) most recently reported earnings on November 14, 2023 for Q4 FY2023, posting EPS of $-0.50 — beating the analyst consensus of $-0.66 by +24.1%. The next CFRXQ earnings date is expected around September 1, 2026.
Each quarter, investors track CFRXQ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CFRXQ revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CFRXQ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CFRXQ earnings · 5 questionsContraFect Corporation's next earnings report is expected around September 1, 2026. CFRXQ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CFRXQ historically reports after market close (AMC).
CFRXQ earnings datewhen is CFRXQ earningsCFRXQ next earnings datewhen does CFRXQ report earningsCFRXQ earnings calendar
▸ Source: FMP · ContraFect Corporation SEC filings · US GAAP · ContraFect Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026